 |
| AI generated image |
What These Drugs Actually Do
Ozempic and Wegovy both contain the exact same active ingredient, semaglutide, made by the same company. The difference comes down to what each is officially approved for and the maximum dose used. Ozempic is approved to treat type 2 diabetes, while Wegovy is approved specifically for weight management and, more recently, for reducing cardiovascular risk. Other GLP-1* drugs, like Mounjaro and Zepbound, work through a similar pathway but contain a different active ingredient.
*GLP-1 drugs are a class of medications that mimic a natural gut hormone (GLP-1) involved in blood sugar control and appetite regulation. Ozempic, Wegovy, Mounjaro, and Zepbound are all examples of GLP-1 or related drugs, though they differ in active ingredient, dose, and approved use.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide (same drug) |
| Officially approved for | Type 2 diabetes | Weight management, and cardiovascular risk reduction in certain patients |
| Maximum weekly dose | Up to 2 mg | Up to 2.4 mg (higher) |
| Used "off-label" for weight loss? | Sometimes, though not its approved use | N/A, this is its approved use |
This distinction matters for this article specifically: the large cardiovascular outcomes trial discussed below used the higher Wegovy dose, and Wegovy is the one that carries the official cardiovascular risk reduction approval. Ozempic, at its lower dose, is expected to have a similar effect given the identical active ingredient, but the formal approval for heart benefit sits with Wegovy.
Yes, It Really Does Improve Cholesterol
A large analysis combining 76 clinical trials and over 39,000 participants found that GLP-1 drugs consistently improved cholesterol and triglyceride levels compared to placebo. Across various studies, people typically see LDL cholesterol drop by around 5 to 10 percent, triglycerides drop by a more noticeable 15 to 25 percent, and HDL cholesterol rise slightly. These aren't massive changes, but they're real and consistent enough to show up across dozens of studies.
How Does a Diabetes and Weight Loss Drug Affect Cholesterol at All?
Part of the answer is simple: losing weight tends to improve cholesterol on its own, regardless of how the weight comes off. Since these drugs often lead to significant weight loss, some improvement would be expected either way.
But here's the more surprising part. Research suggests these drugs may also improve cholesterol through pathways that have nothing to do with weight loss. GLP-1 slows how quickly fat from a meal enters your bloodstream, which reduces the sharp spike in triglycerides that normally follows eating. These drugs also improve insulin sensitivity, and since poor insulin sensitivity tends to push triglycerides up and HDL down, fixing that piece of the puzzle helps the whole lipid picture improve too.
The Study That Changed the Conversation
The most convincing evidence didn't come from a lab report, it came from real health outcomes. The SELECT trial, a major study following over 17,600 people with existing heart disease and obesity but no diabetes, found that semaglutide reduced the combined risk of cardiovascular death, heart attack, and stroke by 20 percent compared to placebo. This was a big deal precisely because these participants didn't have diabetes, meaning the benefit couldn't be explained away as simply "better blood sugar control." Based partly on this trial, Wegovy earned FDA approval in 2024 specifically to reduce cardiovascular risk in this group, not just for weight loss.
Quick Snapshot
| Marker | Typical Change |
|---|---|
| LDL cholesterol | Down about 5 to 10% |
| Triglycerides | Down about 15 to 25% |
| HDL cholesterol | Slight increase |
| Major cardiovascular events (SELECT trial) | 20% relative risk reduction |
Important Reality Check: It's Not a Statin
As encouraging as this sounds, it's worth keeping expectations realistic. A statin typically lowers LDL cholesterol by 30 to 50 percent, several times more than what GLP-1 drugs achieve. These medications aren't prescribed for cholesterol, and they aren't a substitute for statins in people who need one. Think of the cholesterol improvement as a helpful side benefit layered on top of their main purpose, not a replacement for standard cholesterol treatment. In fact, many people benefit most from combining the two approaches, something worth discussing with a doctor rather than assuming one drug covers everything.
One Thing These Drugs Won't Fix
There's an important exception worth knowing. Lp(a), a genetically determined particle we've covered in What Is Lp(a)?, does not appear to respond to weight loss or GLP-1 therapy in the way LDL and triglycerides do. Since Lp(a) levels are set almost entirely by genetics, if you have a family history of early heart disease or previously elevated Lp(a), that risk factor needs its own separate conversation with your doctor, regardless of how well your other numbers respond to these medications.
Frequently Asked Questions
Q: If I start Ozempic, should I stop taking my statin?
No, this isn't something to decide on your own. GLP-1 drugs and statins work through completely different mechanisms and are often used together. Any change to your medication routine should be discussed with your doctor first.
Q: Do I need to be diabetic or overweight to get the cholesterol benefit?
The research showing cholesterol improvement comes primarily from studies in people with type 2 diabetes, obesity, or existing cardiovascular disease. These drugs aren't currently prescribed to people without one of these conditions specifically for cholesterol benefits.
Q: How soon would I see a change in my cholesterol numbers?
Lipid changes have generally been observed within the first few months of treatment in clinical trials, though the exact timeline varies by individual and by which GLP-1 drug is used.
Key Takeaway
GLP-1 medications like Ozempic and Wegovy do improve cholesterol, typically lowering LDL by 5 to 10 percent and triglycerides by 15 to 25 percent, partly through weight loss and partly through separate metabolic effects. More importantly, the SELECT trial showed this translates into real reductions in heart attacks and strokes, not just better numbers on paper. Still, these drugs are a helpful addition to heart health, not a replacement for statins or a solution for genetically driven risk factors like Lp(a). The best results tend to come from combining the right medications with the lifestyle habits already covered throughout this site.
References
- Yao H, Zhang A, Li D, et al. Comparative Effectiveness of GLP-1 Receptor Agonists on Glycaemic Control, Body Weight, and Lipid Profile for Type 2 Diabetes: Systematic Review and Network Meta-Analysis. BMJ. 2024;384:e076410. doi.org/10.1136/bmj-2023-076410
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. doi.org/10.1056/NEJMoa2307563
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults With Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi.org/10.1056/NEJMoa2032183